MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. ATR
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

AptarGroup (ATR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AptarGroup
NYSE•Healthcare•Medical Instruments & Supplies
$124.84+1.79(0.01%)Market closed
Market Cap
$7.92B
P/E
21.8x
P/S
2.0x
P/B
3.0x

AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

C

How this company scores

AverageMetricSide Score: 59/100

Strongest: Cash & Earnings Quality (16/25); weakest: Balance Sheet & Red Flags (13/25).

Profitability15/25
Growth15/25
Balance Sheet & Red Flags13/25
Cash & Earnings Quality16/25
Strengths
Low leverageConsistent free cash flowConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 21.8x5y range 20.3x – 35.1x
P/E 21.8x · below its 20-quarter median

Currently below its 20-quarter median.

P/S · 2.0x5y range 1.9x – 3.0x
P/S 2.0x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 3.0x5y range 3.0x – 4.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 15.0% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $7.92B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$3.93B
5Q
Q. Revenue
$1.03B
3Q
TTM EBITDA
$806.42M
3Q
TTM Op. Income
$477.42M
4Q
Q. Op. Income
$126.72M
2Q
TTM Net Income
$362.88M
3Q
Q. Net Income
$88.01M
21%
EPS
$1.38
18%
Shares Out.
$63.63M
6Q
$3.93B in TTM revenue grew 8.9% YoY, reaching $1.03B last quarter. TTM EBITDA of $806.42M and TTM operating income of $477.42M show growth is flowing through to the bottom line. TTM net income of $362.88M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
20.1%
1%
Op. Margin
12.3%
17%
Net Margin
8.6%
26%
Op. margin of 12.3% is down 2.6% YoY — costs are rising relative to revenue. Net margin at 8.6% Over the past year, operating margin is down 17% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
21.8x
2Q
P/S Ratio
2.0x
4Q
P/B Ratio
3.0x
2Q
At 21.8x P/E, the stock trades within typical market levels. P/S of 2.0x and P/B of 3.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$5.13B
6%
Cash
$190.40M
2Q
Long-Term Debt
$1.12B
109%
Book Value
$2.63B
3Q
D/E Ratio
0.4
115%
Debt/EBITDA
5.4
95%
With $5.13B in assets and $1.12B in long-term debt, D/E is 0.4and book value is $2.63B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 115% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$103.49M
2Q
TTM Free Cash Flow
$310.39M
15%
FCF Margin
7.9%
22%
FCF / Net Income
0.9
3Q
TTM FCF of $310.39M on $103.49M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 15% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 3.0x
· near its 20-quarter median

Currently near its 20-quarter median.

Leverage Risk

Watch

Debt-to-equity has risen 114.7% recently — increasing financial risk even if the current ratio is manageable.